Avastra files for new BioWeld patent

By Ruth Beran
Friday, 16 September, 2005

Sydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives.

Avastra's BioWeld technology joins arteries and veins using a protein solder and has previously used laser light to activate the join.

Avastra has completed two studies to test for patency (free blood flow) in rats following the rejoining of their aortas using BioWeld Tubes with surgical glues. The one week study showed 20 out of 20 rates having successful anastomoses (rejoining) of the aorta and 11 out of 12 were successful in the second study at six weeks. Mean burst pressures were better than achieved with BioWeld using lasers at one week and equivalent at six weeks. Minimal vessel damage was found due to cytotoxicity in any of the animals from glue.

Additional animal studies using surgical glues are underway in both rats and sheep as part of Avastra's development of the BioWeld ETS (end to side) device for joining blood vessels in cardio-vascular procedures.

Avastra recently abandoned the clinical trials of its BioWeld Tube, which were initially halted in June, following unexpected results in an existing long-term animal study.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd